Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Masoud Najafi, Shima Tavakol, Ali Zarrabi & Milad Ashrafizadeh. (2022) Dual role of quercetin in enhancing the efficacy of cisplatin in chemotherapy and protection against its side effects: a review. Archives of Physiology and Biochemistry 128:6, pages 1438-1452.
Read now
Read now
Zhilai Lin, Jianguang Pan, Lei Chen, Xinhang Wang & Yuhua Chen. (2020) MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway. OncoTargets and Therapy 13, pages 8149-8160.
Read now
Read now
Articles from other publishers (10)
Junjie Gu, Jingyi Chen, Shuaixi Xiang, Xikun Zhou & Jing Li. (2023) Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape. Journal of Advanced Research 54, pages 147-179.
Crossref
Crossref
Aleen Khoury, Elias Elias, Stephanie Mehanna, Wassim Shebaby, Krishant M. Deo, Najwa Mansour, Christian Khalil, Katia Sayyed, Jennette A. Sakoff, Jayne Gilbert, Costantine F. Daher, Christopher P. Gordon, Robin I. Taleb & Janice R. Aldrich-Wright. (2022) Novel Platinum(II) and Platinum(IV) Antitumor Agents that Exhibit Potent Cytotoxicity and Selectivity. Journal of Medicinal Chemistry 65:24, pages 16481-16493.
Crossref
Crossref
Nieves Lara-Ureña, Vahid Jafari & Mario García-Domínguez. (2022) Cancer-Associated Dysregulation of Sumo Regulators: Proteases and Ligases. International Journal of Molecular Sciences 23:14, pages 8012.
Crossref
Crossref
Zhao Chen, Lifang Tian, Li Wang, Xiaotao Ma, Fuqian Lei, Xianghui Chen & Rongguo Fu. (2021) TRIM32 Inhibition Attenuates Apoptosis, Oxidative Stress, and Inflammatory Injury in Podocytes Induced by High Glucose by Modulating the Akt/GSK-3β/Nrf2 Pathway. Inflammation 45:3, pages 992-1006.
Crossref
Crossref
Xiaoxia Shi, Yixin Du, Shujing Li & Huijian Wu. (2022) The Role of SUMO E3 Ligases in Signaling Pathway of Cancer Cells. International Journal of Molecular Sciences 23:7, pages 3639.
Crossref
Crossref
Bo Zhang, You‐you Yan, Yang‐qin Gu, Fei Teng, Xu Lin, Xing‐lu Zhou, Jin‐xin Che, Xiao‐wu Dong, Li‐xin Zhou & Neng‐ming Lin. (2021) Inhibition of TRIM32 by ibr‐7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway. Journal of Cellular and Molecular Medicine 26:2, pages 515-526.
Crossref
Crossref
Guo Zhao, Chuan Liu, Xin Wen, Gan Luan, Longxiang Xie & Xiangqian Guo. (2021) The translational values of TRIM family in pan-cancers: From functions and mechanisms to clinics. Pharmacology & Therapeutics 227, pages 107881.
Crossref
Crossref
Sepideh Mirzaei, Kiavash Hushmandi, Amirhossein Zabolian, Hossein Saleki, Seyed Mohammad Reza Torabi, Adnan Ranjbar, SeyedHesam SeyedSaleh, Seyed Omid Sharifzadeh, Haroon Khan, Milad Ashrafizadeh, Ali Zarrabi & Kwang-seok Ahn. (2021) Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies. Molecules 26:8, pages 2382.
Crossref
Crossref
Yu Cai, Wei Ting Gu, Kang Cheng, Pei Feng Jia, Feng Li, Ming Wang, Wei Feng Zhang, Ji Ting Qiu, Zhe Bao Wu & Wei Guo Zhao. (2021) Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner. Biochemical and Biophysical Research Communications 550, pages 134-141.
Crossref
Crossref
Yancheng Ye, Liangcun Zhao, Qingke Li, Caixia Xi, Yinghong Li & Zhengguo Li. (2020)
circ
_0007385 served as competing endogenous
RNA
for
miR
‐519d‐3p to suppress malignant behaviors and cisplatin resistance of non‐small cell lung cancer cells
. Thoracic Cancer 11:8, pages 2196-2208.
Crossref
Crossref